These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 8100040)
21. Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria. Bentz J; O'Connor MP; Bednarczyk D; Coleman J; Lee C; Palm J; Pak YA; Perloff ES; Reyner E; Balimane P; Brännström M; Chu X; Funk C; Guo A; Hanna I; Herédi-Szabó K; Hillgren K; Li L; Hollnack-Pusch E; Jamei M; Lin X; Mason AK; Neuhoff S; Patel A; Podila L; Plise E; Rajaraman G; Salphati L; Sands E; Taub ME; Taur JS; Weitz D; Wortelboer HM; Xia CQ; Xiao G; Yabut J; Yamagata T; Zhang L; Ellens H Drug Metab Dispos; 2013 Jul; 41(7):1347-66. PubMed ID: 23620485 [TBL] [Abstract][Full Text] [Related]
22. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Hunter J; Hirst BH; Simmons NL Pharm Res; 1993 May; 10(5):743-9. PubMed ID: 8100632 [TBL] [Abstract][Full Text] [Related]
23. Toxic digoxin-drug interactions: the major role of renal P-glycoprotein. Koren G; Woodland C; Ito S Vet Hum Toxicol; 1998 Feb; 40(1):45-6. PubMed ID: 9467211 [TBL] [Abstract][Full Text] [Related]
24. Interaction of docetaxel ("Taxotere") with human P-glycoprotein. Shirakawa K; Takara K; Tanigawara Y; Aoyama N; Kasuga M; Komada F; Sakaeda T; Okumura K Jpn J Cancer Res; 1999 Dec; 90(12):1380-6. PubMed ID: 10665657 [TBL] [Abstract][Full Text] [Related]
25. From bench to bedside: utilization of an in vitro model to predict potential drug-drug interactions in the kidney: the digoxin-mifepristone example. Woodland C; Koren G; Ito S J Clin Pharmacol; 2003 Jul; 43(7):743-50. PubMed ID: 12856388 [TBL] [Abstract][Full Text] [Related]
26. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Cavet ME; West M; Simmons NL Br J Pharmacol; 1996 Jul; 118(6):1389-96. PubMed ID: 8832062 [TBL] [Abstract][Full Text] [Related]
27. The role of P-glycoprotein in drug-resistant hematologic malignancies. Dalton WS; Grogan TM; Miller TP Cancer Treat Res; 1991; 57():187-208. PubMed ID: 1686717 [No Abstract] [Full Text] [Related]
28. Interaction of digoxin with antihypertensive drugs via MDR1. Takara K; Kakumoto M; Tanigawara Y; Funakoshi J; Sakaeda T; Okumura K Life Sci; 2002 Feb; 70(13):1491-500. PubMed ID: 11895100 [TBL] [Abstract][Full Text] [Related]
29. Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein. Ushigome F; Takanaga H; Matsuo H; Yanai S; Tsukimori K; Nakano H; Uchiumi T; Nakamura T; Kuwano M; Ohtani H; Sawada Y Eur J Pharmacol; 2000 Nov; 408(1):1-10. PubMed ID: 11070177 [TBL] [Abstract][Full Text] [Related]
30. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. van Helvoort A; Smith AJ; Sprong H; Fritzsche I; Schinkel AH; Borst P; van Meer G Cell; 1996 Nov; 87(3):507-17. PubMed ID: 8898203 [TBL] [Abstract][Full Text] [Related]
31. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. Shoaf SE; Ohzone Y; Ninomiya S; Furukawa M; Bricmont P; Kashiyama E; Mallikaarjun S J Clin Pharmacol; 2011 May; 51(5):761-9. PubMed ID: 20679500 [TBL] [Abstract][Full Text] [Related]
32. Specific inhibitors distinguish the chloride channel and drug transporter functions associated with the human multidrug resistance P-glycoprotein. Mintenig GM; Valverde MA; Sepulveda FV; Gill DR; Hyde SC; Kirk J; Higgins CF Recept Channels; 1993; 1(4):305-13. PubMed ID: 7915949 [TBL] [Abstract][Full Text] [Related]
33. Cellular mechanisms of digoxin transport and toxic interactions in the kidney. Koren G; Klein J; MacLeod S; Silverman M Vet Hum Toxicol; 1986 Dec; 28(6):549-52. PubMed ID: 3538641 [TBL] [Abstract][Full Text] [Related]
34. Effects of quinidine on the renal tubular and biliary transport of digoxin: in vivo and in vitro studies in the dog. Koren G; Klein J; Giesbrecht E; Ben Dayan R; Soldin S; Sellers E; MacLeod S; Silverman M J Pharmacol Exp Ther; 1988 Dec; 247(3):1193-8. PubMed ID: 3204514 [TBL] [Abstract][Full Text] [Related]
35. The anthelminthic agent albendazole does not interact with p-glycoprotein. Merino G; Alvarez AI; Prieto JG; Kim RB Drug Metab Dispos; 2002 Apr; 30(4):365-9. PubMed ID: 11901088 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Fromm MF; Kim RB; Stein CM; Wilkinson GR; Roden DM Circulation; 1999 Feb; 99(4):552-7. PubMed ID: 9927403 [TBL] [Abstract][Full Text] [Related]
38. Transepithelial vinblastine secretion mediated by P-glycoprotein is inhibited by forskolin derivatives. Hunter J; Hirst BH; Simmons NL Biochem Biophys Res Commun; 1991 Dec; 181(2):671-6. PubMed ID: 1684494 [TBL] [Abstract][Full Text] [Related]
39. Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier. Bourasset F; Cisternino S; Temsamani J; Scherrmann JM J Neurochem; 2003 Sep; 86(6):1564-7. PubMed ID: 12950465 [TBL] [Abstract][Full Text] [Related]
40. Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein. Shirai A; Naito M; Tatsuta T; Dong J; Hanaoka K; Mikami K; Oh-hara T; Tsuruo T Biochim Biophys Acta; 1994 Jul; 1222(3):400-4. PubMed ID: 7913624 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]